TROY activates the PI3K/AKT/TBX3 signaling, which helps to maintain the pluripotency of liver CSCs by upregulating the expression of SOX2, NANOG, and OCT4, and promotes cell motility via activating the EMT pathway in HCC 63. The gene discussed is TNFRSF19; the disease is hepatocellular carcinoma.